BAL Fluid Biomarkers in Sarcoma
Recruiting now Phase 2 NCT06815666
Run by University Health Network, Toronto · for 18 and older · All sexes
What this study is about
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
Who can join (things the study team will check)
✅ You may be able to join if…
- Age ≥ 18 years
- Ability to understand and willingness to sign a written informed consent document
- Diagnosed with soft tissue sarcoma
- Undergoing resection of lung lesion as part of standard care
🚫 You may not be able to join if…
- History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years
Where this trial is running
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Who to contact
David Shultz · 416-946-4501 · david.shultz@uhn.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06815666.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.